Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs

Pfizer's Xeljanz (tofacitinib) has finally won a green light from the European Medicines Agency's CHMP for treating rheumatoid arthritis, but its two previous rejections by the panel on safety grounds might curb sales.